BioHealth Capital Region 2022 Q3 News Recap – Keeping Up the Momentum A few of BioBuzz’s favorite stories from late summer/early fall Over the past several months, life sciences companies [….]
BioFactura is joining forces with Rani Therapeutics Holdings, Inc. to assess BioFactura’s BFI-751 biosimilar Stelara (ustekinumab) candidate with Rani’s RaniPill platform technology, which intends to replace subcutaneous or intravenous injection of biologics with pain-free oral dosing, in the form of a ‘robotic’ pill.
According to the California-based biotech, the RaniPill platform technology enables the drug to navigate through the patient’s stomach and enter the small intestine. The RaniPill capsule then goes through a transformation and aligns itself to inject the drug into the intestinal wall.
A key recent hire at Frederick-based BioFactura was biosimilars and scientific affairs expert Rodeina Challand, who joined the BioFactura team as its new VP of Scientific Affairs in late 2021. We caught up with Challand to discuss her background, the biosimilars market landscape, and why she’s excited about what’s next for BioFactura.
Dr. Jeffrey Hausfeld, Chief Medical Officer and Chairman of the Board at Frederick, Maryland’s BioFactura and the Chairman and Co-Founder of the Society of Physician Entrepreneurs (SoPE), recently co-hosted an engaging webinar sponsored by DocWorking, a physician coaching organization.
BioFactura today announced its second contract option activation of $15.9 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance development of an antibody cocktail therapeutic for the treatment of smallpox.
BioFactura recently announced the addition of two new members to their team. Hallison Rodrigue and Trevor Zimmerman both join as Quality Control Analyst IIIs.
BioFactura, a leading developer and manufacturer of biosimilars and biodefense products, is one of the crown jewels of Frederick, Maryland’s growing biotech hub. The company is thriving and has secured strong funding from both private and government sources that see the potential of the company’s StableFast™ biosimilars platform. In May 2021, BioFactura reached an important milestone, announcing that it had moved its first biosimilar product into the clinic.
In a rapidly expanding market, BioFactura is making waves in a big way in 2021. From initiation of a phase 1 study for a biosimilar treatment for people suffering from Crohn’s Disease to a recent transfer agreement with RANI Therapeutics, there’s a lot to be excited about for a company of just under 50 employees.
Since the approval of the first biosimilar drug in the United States six years ago, the market has rapidly expanded and is expected to grow to approximately $23 billion in the U.S. by 2027. And Maryland’s BioFactura anticipates it will be one of the companies at the forefront of this revolution of new medications.
BioFactura Inc. (“BioFactura”), a leading developer of high-value biosimilar and biodefense drugs using its patented StableFast™ platform, announces an agreement with Rani Therapeutics (“Rani”) to assess its Ustekinumab Biosimilar (BFI-751) in combination with Rani’s RaniPill™ platform.